BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9785132)

  • 1. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
    Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
    Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
    Kallakury BV; Sheehan CE; Rhee SJ; Fisher HA; Kaufman RP; Rifkin MD; Ross JS
    Cancer; 1999 Apr; 85(7):1569-76. PubMed ID: 10193948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas.
    Shiozawa T; Xin L; Nikaido T; Fujii S
    Int J Gynecol Pathol; 1997 Oct; 16(4):348-53. PubMed ID: 9421074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.
    Matthews RP; Hutchinson-Colas J; Maiman M; Fruchter RG; Gates EJ; Gibbon D; Remy JC; Sedlis A
    Gynecol Oncol; 1997 May; 65(2):206-12. PubMed ID: 9159326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
    Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG
    Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
    Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J
    Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma.
    Ito K; Sasano H; Yoshida Y; Sato S; Yajima A
    Anticancer Res; 1998; 18(3A):1661-4. PubMed ID: 9673386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
    Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
    Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
    Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
    Nielsen AL; Nyholm HC
    Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.